Sagimet CMO granted 35,000 stock options
Sagimet Biosciences Inc. reported that Chief Medical Officer Andreas Grauer received a grant of stock options.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Sagimet Biosciences Inc. reported that Chief Medical Officer Andreas Grauer received a grant of stock options. The grant covers 35,000 Stock Options (Right to Buy), each exercisable for one share of Series A Common Stock at an exercise price of $7.27 per share.
The options vest in forty-eight equal monthly installments starting on May 28, 2026, conditioned on Dr. Grauer’s continued service on each vesting date. Following this grant, the filing shows Dr. Grauer directly holding 35,000 options under this award.
Insider Trade Summary
Grant/Award: 35,000 shares
Grant/Award
1 txn
Insider
Grauer Andreas
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 35,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 35,000 contracts (Direct)
Footnotes (1)
- F1. The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following May 28, 2026, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Options granted: 35,000 options
Exercise price: $7.27 per share
Underlying shares: 35,000 shares
+3 more
6 metrics
Options granted
35,000 options
Stock Option (Right to Buy) grant to CMO on May 28, 2026
Exercise price
$7.27 per share
Exercise price for Series A Common Stock underlying the options
Underlying shares
35,000 shares
Series A Common Stock underlying the options
Vesting schedule
48 monthly installments
Equal monthly vesting installments after May 28, 2026
Option expiration
May 27, 2036
Expiration date of the granted stock options
Holding after grant
35,000 options
Total options shown following this transaction
Key Terms
Stock Option (Right to Buy), Series A Common Stock, exercise price, vesting, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
Series A Common Stock financial
"underlying_security_title: "Series A Common Stock""
Series A common stock is a specific class of a company’s ordinary shares issued during an early formal funding round, carrying the ownership rights and voting power tied to that class. For investors it signals an early-stage equity claim with potential upside if the business grows, but also greater risk and typically less liquidity than shares in mature, publicly traded firms—imagine buying a seat on a startup’s team before the company has proven itself.
exercise price financial
"conversion_or_exercise_price: "7.2700""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shall vest and become exercisable over forty-eight equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: "2036-05-27T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Sagimet Biosciences (SGMT) report for Andreas Grauer?
Sagimet Biosciences reported that Chief Medical Officer Andreas Grauer received a grant of 35,000 stock options. These options give him the right to buy Series A Common Stock at a fixed $7.27 exercise price, subject to a multi-year vesting schedule and continued service.
How many Sagimet Biosciences (SGMT) options were granted to the Chief Medical Officer?
The Chief Medical Officer, Andreas Grauer, was granted 35,000 stock options. Each option is a right to buy one share of Series A Common Stock at a $7.27 exercise price, with vesting occurring in 48 equal monthly installments after May 28, 2026.
What is the exercise price of Andreas Grauer’s Sagimet Biosciences (SGMT) stock options?
The exercise price for Andreas Grauer’s stock options is $7.27 per share. This means he can purchase Series A Common Stock at $7.27 once the options vest over time, assuming he continues in service through the scheduled vesting dates.
When do the Sagimet Biosciences (SGMT) options granted to Andreas Grauer start vesting?
The options granted to Andreas Grauer start vesting after May 28, 2026. Vesting occurs through forty-eight equal monthly installments, and each installment is contingent on his continued service with Sagimet Biosciences on the relevant vesting date.
How quickly do the Sagimet Biosciences (SGMT) options granted to the CMO vest?
The 35,000 options granted to the Chief Medical Officer vest gradually over forty-eight equal monthly installments. This structure spreads vesting across four years starting after May 28, 2026, and each monthly installment requires his continued service with the company.
What is the total number of Sagimet Biosciences (SGMT) options held after the reported grant?
Following the reported grant, the filing shows Andreas Grauer holding 35,000 stock options under this award. These options are held directly and relate to Series A Common Stock, with vesting tied to ongoing service over a forty-eight month period.
AI-generated analysis. How Rhea-AI works. Not financial advice.
